» Articles » PMID: 34193879

Neoantigens Elicit T Cell Responses in Breast Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jul 1
PMID 34193879
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells. However, their effect on immune responses in the tumour microenvironment remains unclear in breast cancer. We performed whole exome and RNA sequencing of 31 fresh breast cancer tissues and neoantigen prediction from non-synonymous single nucleotide variants (nsSNVs) among exonic mutations. Neoantigen profiles were determined by predictive HLA binding affinity (IC < 500 nM) and mRNA expression with a read count of ≥ 1. We evaluated the association between neoantigen load and expression levels of immune-related genes. Moreover, using primary tumour cells established from pleural fluid of a breast cancer patient with carcinomatous pleurisy, we induced cytotoxic T lymphocytes (CTLs) by coculturing neoantigen peptide-pulsed dendritic cells (DCs) with autologous peripheral lymphocytes. The functions of CTLs were examined by cytotoxicity and IFN-γ ELISpot assays. Neoantigen load ranged from 6 to 440 (mean, 95) and was positively correlated to the total number of nsSNVs. Although no associations between neoantigen load and mRNA expression of T cell markers were observed, the coculture of neoantigen-pulsed DCs and lymphocytes successfully induced CTLs ex vivo. These results suggest that neoantigen analysis may have utility in developing strategies to elicit T cell responses.

Citing Articles

Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients.

Wagutu G, Gitau J, Mwangi K, Murithi M, Melly E, Harris A Front Oncol. 2024; 14:1444327.

PMID: 39723380 PMC: 11668681. DOI: 10.3389/fonc.2024.1444327.


Identification of BRCA new prognostic targets and neoantigen candidates from fusion genes.

Zhang P, Chu Q Discov Oncol. 2024; 15(1):805.

PMID: 39692896 PMC: 11655931. DOI: 10.1007/s12672-024-01571-3.


Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.

Nandi D, Sharma D Front Immunol. 2024; 15:1477980.

PMID: 39555066 PMC: 11563812. DOI: 10.3389/fimmu.2024.1477980.


Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.

Osumi H, Shinozaki E, Nakamura Y, Esaki T, Yasui H, Taniguchi H Nat Commun. 2024; 15(1):5885.

PMID: 39003289 PMC: 11246505. DOI: 10.1038/s41467-024-50026-4.


Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.

Chaudhry Z, Boyadzhyan A, Sasaninia K, Rai V Antibodies (Basel). 2024; 13(2).

PMID: 38920970 PMC: 11200483. DOI: 10.3390/antib13020046.


References
1.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

2.
Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

3.
Bai X, Ni J, Beretov J, Graham P, Li Y . Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 2018; 69:152-163. DOI: 10.1016/j.ctrv.2018.07.004. View

4.
Schumacher T, Scheper W, Kvistborg P . Cancer Neoantigens. Annu Rev Immunol. 2018; 37:173-200. DOI: 10.1146/annurev-immunol-042617-053402. View

5.
Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View